Exelixis Owners Keep Getting A Bigger Slice Of A Company In Transition

A buyback funded by one oncology drug is concentrating each holder’s claim while the next franchise waits on a regulatory decision.

Exelixis (EXEL) has gained 42.8% over the past twelve months and trades about 5% below its 52-week high, so this is not a stock the market has given up on. Something more mechanical is running underneath the price: the company is retiring its own shares fast enough to change what one share represents, all while the molecule meant to be its next franchise waits on a regulatory decision.

Eight Percent Of The Share Count Went Away In A Year

Over the past year Exelixis spent about $1.1 billion on its own stock and cut shares outstanding by 8.0%. For an owner who did nothing, the same holding now carries a larger claim on the same business. The effect lands in the earnings line: over the last three years net income grew 76.0% a year on average, while earnings per share grew 89.1% a year on average. That gap is not better operations, it is a smaller denominator.

The Whole Engine Is One Molecule, Royalties Included

CABOMETYX is the most prescribed TKI in renal cell carcinoma and the market leader among oral therapies in second-line-plus neuroendocrine tumors, and the cabozantinib franchise generated $573 million of US net product revenue in the second quarter of 2026, roughly 10% more than a year earlier. The royalty line is the same molecule, sold by partners. Exelixis converts 47.5% of revenue into free cash flow, and that cash is what funds the buyback. Cash generation of that kind is what the Trefis High Quality Portfolio favors in its holdings.

The Guidance Came Down And Projected Cash Flow Did Not

With its second-quarter 2026 results Exelixis cut its 2026 total revenue guidance to $2.50 billion to $2.55 billion, which management said lowers the midpoint by $50 million, and attributed the cut to a more gradual ramp for the neuroendocrine tumor indication. It also took $50 million off the research and development midpoint, and management pairs that trimming with keeping its projected free cash flow essentially unchanged. The projection held on the expense line, not the revenue line. After accounting for stock-based compensation, the cash returned is a 7.4% yield on market value, and free cash flow covers that outlay about 1.0 times, with a net cash position of roughly $673 million on the balance sheet as the cushion.

Sixteen Times Earnings, With The Second Franchise Still Unapproved

The stock trades at 15.8 times trailing earnings, which is undemanding for a business converting nearly half its revenue into cash. It has returned 152% in price over the last three years, against 81% for the S&P 500, and share retirement is only one driver of that, alongside earnings growth and changes in the valuation multiple. The next leg rests on zanzalintinib: seven ongoing or imminent pivotal trials, a colorectal cancer filing under review with a decision date in early December 2026, and a third-line-plus CRC setting management sizes at roughly 23,000 US patients and a $1.5 billion opportunity. The engine is real and self-funded, and the multiple is not the problem; one risk is sequencing, because the guidance came down before the second franchise arrived. The capital compounders screen shows whether share retirement at this rate is unusual or ordinary.

When A Compounder Becomes Most Of Your Portfolio

Great compounders have a way of quietly becoming most of a portfolio, which is wonderful right up until it is not. Concentration tends to arrive by accident rather than by decision. What your largest position would do to your net worth is exactly what the Trefis Wealth team computes, with the same rules-based systematic discipline that runs our High Quality Portfolio. Request a free vulnerability audit of your biggest positions.